Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Sun L, Thorson T, Zhu R, Huo J, Tong J, Rodgers WH, et al. A case report of parotid mammary analogue secretory carcinoma and reviews. Int J Surg Case Rep. 2019;55:88-91.

Cao C, Oswald AB, Fabella BA, Ren Y, Rodriguiz R, Trainor G, et al. The Ca1.2 L-type calcium channel regulates bone homeostasis in the middle and inner ear. Bone. 2019;125:160-168.

Reina-Campos M, Linares JF, Duran A, Cordes T, L'Hermitte A, Badur MG, et al. Increased Serine and One-Carbon Pathway Metabolism by PKCλ/ι Deficiency Promotes Neuroendocrine Prostate Cancer. Cancer Cell. 2019;35(3):385-400.e9.

Nissim S, Leshchiner I, Mancias JD, Greenblatt MB, Maertens O, Cassa CA, et al. Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer. Nat Genet. 2019;51(9):1308-1314.

Li F, Deng Z, Zhang L, Wu C, Jin Y, Hwang I, et al. ATRX loss induces telomere dysfunction and necessitates induction of alternative lengthening of telomeres during human cell immortalization. EMBO J. 2019;38(19):e96659.

Ahmed A, Crowson N, Magro CM. A comprehensive assessment of cutaneous Rosai-Dorfman disease. Ann Diagn Pathol. 2019;40:166-173.

Rodrigues G, Hoshino A, Kenific CM, Matei IR, Steiner L, Freitas D, et al. Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat Cell Biol. 2019;21(11):1403-1412.

Cohn CS, Allen ES, Cushing MM, Dunbar NM, Friedman DF, Goel R, et al. Critical developments of 2018: A review of the literature from selected topics in transfusion. A committee report from the AABB's Clinical Transfusion Medicine Committee. Transfusion. 2019;59(8):2733-2748.

Gomez-Arteaga A, Margolskee E, Wei MT, Van Besien K, Inghirami G, Horwitz S. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leuk Lymphoma. 2019;60(7):1626-1631.

Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, et al. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci Transl Med. 2019;11(484).